Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/development-of-a-pd-l1-complementary-diagnostic-immunohistochemistry-hEbiOqI00b
References (21)
-
O. Akbari, Peter Stock, A. Singh, V. Lombardi, W. Lee, G. Freeman, A. Sharpe, D. Umetsu, R. DeKruyff (2010)
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directionsMucosal Immunology, 3
-
Therese Phillips, P. Simmons, H. Inzunza, J. Cogswell, J. Novotny, C. Taylor, Xiaoling Zhang (2015)
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung CancerApplied Immunohistochemistry & Molecular Morphology, 23
-
Koichiro Matsumoto, S. Fukuyama, Miyuki Eguchi-Tsuda, T. Nakano, Takafumi Matsumoto, M. Matsumura, Atsushi Moriwaki, Keiko Kan-o, Y. Wada, H. Yagita, T. Shin, D. Pardoll, Rirprajak Patcharee, M. Azuma, Y. Nakanishi, H. Inoue (2008)
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma.Biochemical and biophysical research communications, 365 1
-
L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazières, Keunchil Park, David Smith, A. Artal-Cortes, C. Lewanski, F. Braiteh, D. Waterkamp, P. He, W. Zou, Daniel Chen, J. Yi, A. Sandler, A. Rittmeyer (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 387
-
Y. Latchman, Spencer Liang, Yin-Xia Wu, T. Chernova, R. Sobel, M. Klemm, V. Kuchroo, G. Freeman, A. Sharpe (2004)
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.Proceedings of the National Academy of Sciences of the United States of America, 101 29
-
Daniel Chen, Bryan Irving, Stephen Hodi (2012)
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 18
-
L. Emens, S. Adams, S. Loi, A. Schneeweiss, H. Rugo, E. Winer, C. Barrios, V. Diéras, J. Haba-Rodriguez, L. Gianni, S. Chui, P. Schmid (2016)
IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).Journal of Clinical Oncology, 34
-
D. McDermott, J. Sosman, M. Sznol, C. Massard, M. Gordon, O. Hamid, J. Powderly, J. Infante, M. Fassò, Yan Wang, W. Zou, P. Hegde, G. Fine, T. Powles (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 8
-
J. Rosenberg, J. Hoffman-Censits, T. Powles, M. Heijden, A. Balar, A. Necchi, N. Dawson, P. O’Donnell, A. Balmanoukian, Y. Loriot, S. Srinivas, M. Retz, P. Grivas, R. Joseph, M. Galsky, M. Fleming, D. Petrylak, J. Pérez-Gracia, H. Burris, D. Castellano, C. Canil, J. Bellmunt, D. Bajorin, D. Nickles, R. Bourgon, G. Frampton, N. Cui, S. Mariathasan, O. Abidoye, G. Fine, R. Dreicer (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 387
-
D. Spigel, J. Chaft, S. Gettinger, B. Chao, L. Dirix, P. Schmid, L. Chow, C. Chappey, M. Kowanetz, A. Sandler, R. Funke, N. Rizvi (2015)
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 33
-
L. Horn, D. Spigel, S. Gettinger, S. Antonia, M. Gordon, R. Herbst, L. Sequist, C. Chappey, M. Kowanetz, A. Sandler, J. Soria (2015)
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.Journal of Clinical Oncology, 33
-
F. Hirsch, A. McElhinny, D. Stanforth, J. Ranger-Moore, M. Jansson, K. Kulangara, William Richardson, P. Towne, D. Hanks, B. Vennapusa, A. Mistry, R. Kalamegham, S. Averbuch, J. Novotny, E. Rubin, K. Emancipator, I. McCaffery, A. Williams, Jill Walker, J. Longshore, M. Tsao, K. Kerr (2017)
PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology, 12
-
Daniel Chen, I. Mellman (2013)
Oncology meets immunology: the cancer-immunity cycle.Immunity, 39 1
-
D. Petrylak, T. Powles, J. Bellmunt, F. Braiteh, Y. Loriot, C. Zambrano, H. Burris, Joseph Kim, S. Teng, J. Bruey, P. Hegde, O. Abidoye, N. Vogelzang (2015)
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).Journal of Clinical Oncology, 33
-
Roy Herbst, J. Soria, M. Kowanetz, G. Fine, O. Hamid, M. Gordon, Jeffery Sosman, David McDermott, J. Powderly, S. Gettinger, H. Kohrt, L. Horn, Donald Lawrence, S. Rost, M. Leabman, Yuanyuan Xiao, A. Mokatrin, H. Koeppen, P. Hegde, I. Mellman, Daniel Chen, F. Hodi (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 515
-
(2016)
KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced NSCLC with a PD-L1 TPS ≥ 50 -
T. Powles, J. Eder, G. Fine, F. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. Burris, D. Petrylak, S. Teng, Xiao-dong Shen, Z. Boyd, P. Hegde, Daniel Chen, N. Vogelzang (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 515
-
Y. Latchman, C. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Yoshiko Iwai, A. Long, Julia Brown, Raquel Nunes, E. Greenfield, K. Bourque, V. Boussiotis, Laura Carter, B. Carreno, Nelly Malenkovich, H. Nishimura, Taku Okazaki, T. Honjo, A. Sharpe, G. Freeman (2001)
PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2
-
(2016)
CheckMate 026: a phase III trial of nivolumab vs investigator’s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death ligand 1–positive NSCLC -
W. Schütte, F. Barlesi, K. Park, F. Ciardiello, J. Pawel, S. Gadgeel, T. Hida, D. Kowalski, M. Dols, D. Cortinovis, J. Leach, J. Polikoff, D. Gandara, C. Barrios, Ds Chen, P. He, M. Ballinger, D. Waterkamp, A. Sandler, A. Rittmeyer (2017)
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLCPneumologie, 71
-
Julia Brown, D. Dorfman, F. Ma, Elizabeth Sullivan, O. Muñoz, C. Wood, E. Greenfield, G. Freeman (2003)
Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1The Journal of Immunology, 170
- Publisher
- Wolters Kluwer Health
- Copyright
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
- ISSN
- 1541-2016
- eISSN
- 1533-4058
- DOI
- 10.1097/PAI.0000000000000594
- Publisher site
- See Article on Publisher Site
Abstract
Supplemental Digital Content is available in the text.
Journal
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Feb 1, 2019